Iberdomide Plus Dexamethasone for Heavily Pretreated Late-Line Relapsed/Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial
Lancet Haematol 2022 Oct 06;[EPub Ahead of Print], S Lonial, R Popat, C Hulin, S Jagannath, A Oriol, PG Richardson, T Facon, K Weisel, JT Larsen, MC Minnema, AO Abdallah, AZ Badros, S Knop, EA Stadtmauer, Y Cheng, M Amatangelo, M Chen, TV Nguyen, A Amin, T Peluso, NWCJ van de DonkFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.